The combination of nivolumab and ipilimumab was also evaluated in checkmate-649 [10], which was a phase III trial assessing nivolumab plus chemotherapy or ipilimumab versus chemotherapy alone as a first-line treatment in patients with non-HER-2-positive advanced gastric, gastroesophageal junction, or esophageal cancer—all with adenocarcinoma histology. Here, ERBB2 is linked to esophageal cancer.